Having watched a lot of life science business development teams, the difference between the ones that hit their number and the ones that grind is almost never talent, effort, or messaging. It is timing, and timing is a function of information.
The teams that win are not better at selling
This is uncomfortable but consistently true. The winning team’s reps are not more persuasive. Their decks are not better. Their pricing is often worse.
What they have is a systematic answer to one question: who should we call this week, and why? They arrive early, with a reason, to companies that have just developed a need. Everyone else arrives late, without a reason, to companies chosen alphabetically.
You cannot out-sell a timing disadvantage. If a competitor is talking to the buyer during scoping and you are calling after the RFP, you are competing on price in a process someone else shaped.
The three failure modes
- Late. The information arrives after the window closed. This is the most common and least visible failure, because you never learn about the deals you were not invited to.
- Untriggered. The rep has names but no reason, so outreach is generic and gets deleted, and the rep concludes the market is quiet.
- Untranslated. The team reads the news but never converts it into action. Everyone at the company knew about the acquisition. Nobody worked out that it meant a manufacturing transfer and a call to technical operations this quarter.
Why this is not a people problem
The instinctive response is to coach the reps, rewrite the templates, or change the comp plan. None of that works, because none of it addresses the constraint.
A rep cannot act on an event they do not know about. A rep who spends ten hours a week trying to find those events has eight hours left to sell. The bottleneck is upstream of the sales conversation entirely, which is why sales training so rarely moves the number in this industry.
What good looks like
Monday morning, every rep opens a short list: these companies had something happen, here is what it means for our service, here is who to contact, here is why they will take the call. Fifteen minutes of reading. A week of well-aimed outreach.
That is not a fantasy of sales enablement. It is just the difference between a team that knows what happened and a team that finds out later.
Know who to call
Your competitors are not better at selling than you. They just know things earlier. That is a fixable disadvantage.
Get Signals for your BD team, $8,000/year for up to 5 seats
Or a single seat, $2,500/year
Every Friday: 15 to 20 tagged signals, a “Who To Call This Week” list of 10 prioritized targets with the trigger and a suggested opening line, and a monthly outreach playbook. Two-week free trial, no commitment. See also the buying signals biotech vendors keep missing.
Frequently asked questions
What separates high-performing life science BD teams?
Timing, not talent. The winning teams are not more persuasive and often have worse pricing, but they have a systematic answer to who to call this week and why. They arrive early with a reason to companies that just developed a need, while others arrive late without a reason to companies chosen alphabetically.
Why does sales training rarely fix biotech BD performance?
Because the constraint is upstream of the sales conversation. A rep cannot act on an event they do not know about, and a rep spending ten hours a week hunting for those events has eight hours left to sell. Coaching, templates and comp plans do not address an information bottleneck.
What are the common failure modes in life science BD?
Being late, where information arrives after the buying window closed, which is invisible because you never learn about deals you were not invited to. Being untriggered, where reps have names but no reason to call. And being untranslated, where the team reads the news but never converts it into a specific action and a specific call.
